GA-VENTIV-TECHNOLOGY
21.7.2022 11:02:06 CEST | Business Wire | Press release
Ventiv Technology, the leading provider of risk, insurance and underwriting solutions, announced today its inclusion in the Management des Risques et des Assurances de l’Entreprise’s (AMRAE) 2022 Panorama report as leaders in Analytics and Insurance. The association’s 14th annual market analysis is based on vendor and risk manager questionnaires. Among the 55 vendors evaluated, Ventiv was one of only four to be recognized as a leader in the artificial intelligence quadrant, having both functional and technical coverage. Ventiv was one of five vendors to have that same distinction in the insurance quadrant.
According to the report, 63% of risk managers look for one tool to meet all their functional needs, audit, risk management, insurance, internal control, etc., highlighting the growing industry trend towards converging risk management systems that are cross-functional.
“Ventiv continues to grow and expand its offerings to stay on the forefront of tech and innovation,” said Steve Cloutman, Managing Director of Ventiv. “This year's report reinforces known trends and where we are headed as an industry. We look forward to continuing to be a part of moving the industry forward.”
The report also found that ease of use and reporting capabilities are the top two criteria risk managers seek when evaluating a RMIS platform. In addition, the report listed AI as one of the top three functionalities that are on the agenda for future development for most firms.
Ventiv is a differentiator when it comes to its AI-powered data analytics software. Its AI and machine learning algorithms help clients predict outcomes, prioritize time and resources, and improve operational efficiency. Combined with the company’s hands-on customer support and software offerings, clients can easily scale their risk management programs as they grow.
With more than 450 clients across Europe, North America, and Asia, Ventiv provides RMIS solutions to some of the largest global companies across a range of industries, including healthcare, manufacturing, and hospitality. This is the company’s first year being included in the report which was submitted in collaboration with EY.
The AMRAE Panorama Report is an annual publication that presents a global view of RMIS trends, market practices and details on the latest technology in the marketplace. Since 2008 AMRAE has approached the survey with a neutral point of view to provide valuable insights for risk management professionals looking for the latest info on RMIS.
Download the full report or visit Ventiv’s website for more information.
About Ventiv Technology
Ventiv Technology is a leading global provider of risk management information systems (RMIS), enterprise risk management (ERM), insurance claims, billing, policy, and administration technology integrated with its market-leading analytics and predictive models. Ventiv Technology’s SaaS and on-prem solutions are deployed by brokers, insured corporate entities, federal and regional governments, third party claims administrators (TPAs), and risk pools across a variety of industries including transportation & logistics, retail, financial services, leisure & hospitality, carriers & insurers, energy, aviation, manufacturing, government & public entities, and many more.
With over 45 years’ experience, Ventiv proudly boasts over 450 institutions as its customers and more than 350,000 users of Ventiv’s technology in over 40 countries. Ventiv’s global footprint and experienced team of industry veterans delivers insight to organizations that allows our customers to predict, manage, and respond to risk.
For more information, please visit https://www.ventivtech.com or @VentivTech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom